Clinicopathologic features and clinical outcome differences in de novo versus secondary histiocytic sarcomas: A multi-institutional experience and review of the literature
Histiocytic sarcomas (HS) are rare neoplasms that generally behave aggressively, yet an in-depth look at the clinicopathologic features has not been studied. This paper explores 23 unique HS occurring as de novo or secondary malignancies. Patients with a secondary HS had lower mean survival by 58.2 months (p=0.001). This suggests secondary HS behaves more aggressively than de novo HS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Devin R. Broadwater, Joanna L. Conant, David R. Czuchlewski, Jordan M. Hall, Shi Wei, Gene P. Siegal, Deniz Peker Tags: Original Study Source Type: research
More News: Cancer & Oncology | Genetics | Hematology | Jordan Health | Leukemia | Lymphoma | Middle East Health | Myeloma | Sarcomas | Study